Radiopharmaceuticals Market is segmented By Radioisotopes (Tec.99, F18, Iodine 131, Lutetium 177, Yttrium 90, Gallium 68, Gallium 67, Rubidium 82, Iodine 123, Iodine 125, Indium 111, Others), By Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others), By Source (Cyclotrons, Nuclear Reactor), By End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgical Centers, Cancer Research Institute), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Radiopharmaceuticals Market Size
Radiopharmaceuticals Market size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate CAGR of 6.2% over the forecast period 2024-2031.
Radiopharmaceuticals contain radioactive substances used to diagnose or treat diseases, including cancer or cardiology. These are used for the diagnosis of abscess and infections, blood vessel diseases, bone diseases, colorectal disease and others.
Radiopharmaceuticals Market Summary
|
Metrics |
Details |
|
Market CAGR |
6.2% |
|
Segments Covered |
By Radioisotopes, By Application, By Source, By End User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Radiopharmaceuticals Market Trends
The radiopharmaceuticals market growth is driven by the rise in prevalence of different diseases such as cancer, and neurological disorders, rising adoption of radiopharmaceuticals for diagnosis and treatment of diseases, increase in the geriatric population, and research and development activities.
The rising product development in radiopharmaceutical is expected to drive the market growth
The rising prevalence of diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. According to the National Cancer Institute October 2020 data report, researchers have recently designed and tested radiopharmaceuticals for various cancers as diverse as lung, melanoma, colorectal, and leukemia. Also, researchers have repurposed, such as Lutetium Lu 177, targeting molecules to carry more potent radioactive compounds, or isotopes, instead ones that could kill cancer cells instead of simply helping visualize them. For instance, prostate cancer has been an early testing ground for this repurposing. PSMA is found in large amounts and almost exclusively on prostate cells. Fusing a molecule that binds PSMA to a radioactive compound is used in PET scan imaging.
Moreover, using radiopharmaceuticals in combination with other therapies may be one way to drive that improvement. Some researchers are now testing radiopharmaceuticals combined with radiation sensitizers—drugs that make cancer cells even more vulnerable to radiation. For example, a clinical trial of lutetium Lu 177-dotatate combined with a radiation sensitizer called triapine, blocks cells from producing the compounds needed for DNA repair after radiation-induced damage.
The disadvantages of radiopharmaceuticals therapy will hamper the growth of the market
However, the disadvantages of radiopharmaceutical therapy include radiation risks, images that are not usually disease-specific, in this therapy typically requiring injection into the bloodstream, disposal of radioactivity waste and high cost of the treatment. These factors are restraining the market growth.
COVID-19 Impact Analysis on Radiopharmaceuticals Market
The appearance of COVID-19 considerably impacted the global radiopharmaceuticals market. The coronavirus-19 disease (COVID-19) pandemic has undoubtedly posed significant challenges to healthcare systems globally. According to a statement by Pfizer, one of the greatest effects of COVID-19 on cancer patients is fear due to surgery and clinical trial disruptions. In addition, Cancer Research UK reported in April 2020 that a considerable number of early cancers would go undiagnosed, as there was a significant reduction in the number of people being screened for bowel, breast and cervical cancer across the UK, approximately 200,000 fewer per week than before the pandemic. There was also a significant decrease in radiotherapy treatment courses, nearly 20 % in April 2020, 6.2 % in May and 11.6 % in June, compared to the same months in 2019.
In addition, some organizations are conducting their studies even during a pandemic. For instance, the Cancer Research Institute (CRI) reported the results of a survey of 36 investigators conducting cancer clinical trials at institutions around the world. In 2022 situation is recovering from COVID-19, and the patient can access the proper treatments, leading to market growth of radiopharmaceutical therapy worldwide.
Radiopharmaceuticals Market Segmentation Analysis
The oncology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The oncology segment is expected to boost the market throughout the forecast. The article was published in Future Oncology in June 2020; reported that, as per the WHO, worldwide cancer cases are predicted to increase around 60%, from 18.1 million in 2018 to 29.4 million by 2040. Also, as per the article published in Nature Reviews Drug Discovery in July 2020, several radiopharmaceutical therapy (RPT) agents are currently on the market, with many more in development. For instance, Bayer is developing Radium-223 chloride for Bone metastasis, Novartis is developing 177Lu-labelled DOTATATE for Neuroendocrine tumors, and Telix Pharma developing 211At-labelled aLAT-1a for Multiple myeloma. These include four β-particle and five α-particle emitters. Lead-212 decays to bismuth-212 and is used to deliver 212Bi, an α-emitter, without being constrained by its 1-hour half-life. Of the 30 RPT agents mentioned in the article, 13 deliver radionuclides that decay by α-particle emission. The interest in α-emitters reflects a potential growth area in RPT. The development of the RPT is increasing as the incidence and demand for treatment are rising, leading to the oncology segment growth in the market.
Global Radiopharmaceuticals Market Geographical Share
North America region holds the largest market share of the global radiopharmaceuticals market
North America dominates the radiopharmaceutical market and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to rising cancer and another disease, advanced healthcare, launching new products and the presence of many key players. In July 2022, according to the Centers for Disease Control and Prevention, About 20.1 million adults age 20 and older have CAD (about 7.2%). With the rising incidence of disease, there is a demand for suitable treatment in the North American region.
In addition, the key players are adopting market strategies to expand their business. For instance, in November 2020, Canadian radiopharmaceuticals leading company Fusion Pharmaceuticals collaborated with Anglo-Swedish Pharma leader AstraZeneca to commercialize and develop next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Also, in July 2022, PETNET Solutions Inc., a Siemens Healthineers company and the leading manufacturer of radiopharmaceuticals for positron emission tomography (PET) imaging in the United States, opened a new radiopharmacy in Florida, United States.
Radiopharmaceuticals Companies and Competitive Landscape
The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens AG, Positron Corporation, Curium, GE Healthcare, Lantheus Holdings Inc., Sotera Health LLC, Bayer AG, Eckert & Ziegler, Novartis AG, and BWX Technologies Inc. among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.
For instance,
In March 2021, Aktis Oncology, a biotechnology company developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancer cases, announced the completion of a series for solid tumors.
Novartis AG
Overview:
Novartis AG is a Swiss-American multinational pharmaceutical company founded in 1996 and headquartered in Switzerland. The company offers radiopharmaceutical products, including gallium Ga 68, for treating diseases such as cancer, cardiology, neurology and infectious & inflammatory diseases.
Product Portfolio:
PLUVICTO: The PLUVICTO brand name for lutetium Lu 177 vipivotide tetraxetan is used for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who has been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
The global radiopharmaceuticals market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.
